
"Sector" = median of Healthcare across 84 companies
Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease and critical care monitoring. The company specializes in heart valve therapies, particularly transcatheter aortic valve replacement (TAVR) systems, and hemodynamic monitoring technologies. Edwards is headquartered in Irvine, California, and operates primarily in the medical devices industry within the healthcare sector.
Edwards generates revenue through two main segments: Transcatheter Aortic Valve Replacement (TAVR) and Surgical Structural Heart, and Critical Care. The TAVR segment, which accounts for the majority of sales, includes the Sapien family of valves and delivery systems. The Critical Care segment provides advanced monitoring platforms for measuring cardiac output and hemodynamics. Revenue is derived from product sales to hospitals and medical centers, with a growing focus on international markets.
The company operates in the highly competitive medical devices industry, focusing on structural heart disease. Key competitors include Medtronic, Boston Scientific, and Abbott Laboratories. Edwards holds a strong market position in TAVR, benefiting from first-mover advantage and continuous innovation. The high gross margin of 78% reflects its premium pricing and proprietary technology. The company's R&D investments aim to expand into new indications such as mitral and tricuspid valve therapies.
Edwards' primary customers are hospitals, cardiac catheterization labs, and surgical centers worldwide. Its target audience includes interventional cardiologists, cardiac surgeons, and critical care physicians. Geographically, the US is the largest market, followed by Europe and Japan. Emerging markets in Asia and Latin America present growth opportunities as TAVR adoption increases. The company's products address an aging population with rising prevalence of aortic stenosis and other structural heart conditions.
An auto-generated descriptive profile based on company data, for informational purposes only.
No 24-hour summary has been generated yet.
Latest saved period: March 2026 · 2026-03-31
Cash dividends by ex-date, not an investment recommendation.
Wrqti brings Edwards Lifesciences Corporatio data into one page covering available price, financial statements, valuation ratios, margins, cash-flow metrics, news, and alerts. This page helps you understand the numbers and is not a buy or sell recommendation.
Companies in the Healthcare sector you can compare with Edwards Lifesciences Corporatio:
When available, the page shows quarterly and annual statements plus ratios such as PE, price to book, profit margin, and free cash flow. Latest financial period shown: March 2026.
Wrqti content depends on available data and third-party sources and may include delays or errors. Review official company filings and consult a licensed financial advisor before making investment decisions. Read the data methodology.